Elsevier

Neuropharmacology

Volume 99, December 2015, Pages 379-386
Neuropharmacology

Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum

https://doi.org/10.1016/j.neuropharm.2015.08.008Get rights and content

Highlights

  • MP-10 dose dependently increased c-Fos positive neurons in the rat neostriatum.

  • DLS showed greater activation of c-Fos than the DMS following MP-10 treatment.

  • MP-10-induced c-Fos was greater in D1(−) than in D1(+) in Drd1a-tdTomato mice.

Abstract

Studies described here tested the hypothesis that phosphodiesterase 10A inhibition by a selective antagonist, MP-10, activates the dopamine D2 receptor expressing medium spiny neurons to a greater extent than the D1 receptor expressing neurons. We used regional pattern of c-Fos induction in the neostriatal subregions of rodents and direct assessment of D1-positive and -negative neurons in the DRd1a-tdTomato mice for the purpose. MP-10 (1, 3, 10 or 30 mg/kg, PO) dose-dependently increased c-Fos immunopositive nuclei in all regions of neostriatum. However, the effect was statistically greater in the dorsolateral striatum, a region known to be activated preferentially by the D2 antagonism, than the D1-activated dorsomedial striatum. The D2 antagonist, haloperidol (0.3, 1, or 3 mg/kg, PO) produced an identical, regional pattern of c-Fos induction favoring the dorsolateral striatum of the rat. In contrast, the D1 agonist, SKF82958 (0.5, 1, or 2 mg/kg, PO), induced greater expression of c-Fos in the dorsomedial striatum. The C57Bl/6 mouse also showed regionally preferential c-Fos activation by haloperidol (2 mg/kg, IP) and SKF82858 (3 mg/kg, IP). In the Drd1a-tdTomato mice, MP-10 (3 or 10 mg/kg, IP) increased c-Fos immunoreactivity in both types of neurons, the induction was greater in the D1-negative neurons. Taken together, both the regional pattern of c-Fos induction in the striatal sub-regions and the greater induction of c-Fos in the D1-negative neurons indicate that PDE10A inhibition produces a small but significantly greater activation of the D2-containing striatopallidal pathway.

Introduction

The medium spiny neurons (MSN) of the neostriatum are the primary target of antipsychotic and anti-parkinsonian medications. Specifically, these drugs target the Gαi-coupled dopamine D2 family of G protein-coupled receptors on the MSNs (Perreault et al., 2011). Morphological and functional studies have shown that the D2 receptor-expressing MSNs constitute the striatopallidal pathway whereas the Gαs-coupled D1 expressing cells form the striatonigral pathway (Gerfen, 1992). Classical antipsychotic drugs are thought to produce their efficacy by antagonizing the D2 receptors (Kapur and Mamo, 2003). However, these drugs also induce extrapyramidal motor side effects by reducing basal ganglia output (Parr-Brownlie and Hyland, 2005). Although the newer, so-called atypical antipsychotics have a reduced liability to trigger extrapyramidal side effects, they induce intolerable metabolic side effects (Manu et al., 2012). Therefore, it remains critical to identify additional therapeutic mechanisms for treatment of psychotic symptoms associated with schizophrenia and other psychiatric disorders.

Phosphodiesterases (PDEs) are a family of enzymes that cleave cyclic nucleotides and thereby regulate second messenger signaling casacades (Sharma et al., 2013). PDE10A, like several other PDEs, cleaves both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) to AMP and GMP, respectively (Wilson and Brandon, 2015). PDE10A is particularly relevant to the basal ganglia system because it is highly enriched in MSNs (Kleiman et al., 2011, Seeger et al., 2003). MP-10 (also known as PF-2545920; 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline) is a potent and selective PDE10A inhibitor (PDE10i) both in vitro and in vivo (Schulke et al., 2014). Treatment with MP-10 increases intracellular concentrations of cAMP/cGMP, augmenting dopamine D2 receptor antagonist- and dopamine D1 receptor agonist-mediated effects (Grauer et al., 2009, Schmidt et al., 2008). Given that dopamine D2 receptor inhibition is a pharmacological activity shared by all antipsychotic drugs, PDE10i have been proposed as a new class of therapeutics to treat psychoses (Strick et al., 2010).

The PDE10A knockout mice show reduced locomotor activity (Siuciak et al., 2006, Siuciak et al., 2008). Hence, we hypothesize that although PDE10i will affect activity of all MSNs, it may induce relatively greater activation of D2(+) MSNs. The present set of studies tested this hypothesis using MP-10 as a pharmacological probe. We assessed c-Fos immunoreactivity as a marker of increased neuronal activity in two sub-regions of the neostriatum, the dorsolateral and dorsomedial striatum, preferentially regulated by dopamine D2 and D1 receptors, respectively (Merchant et al., 1994). The regional pattern of c-Fos induction by MP-10 was compared to that produced by acute treatment with, prototypical D2 antagonist, haloperidol and, D1 agonist, SKF82958. Finally, to directly confirm this effect, we utilized the bacterial artificial chromosome (BAC) transgenic Drd1a-tdTomato mice line 6 (Ade et al., 2011) to assess co-localization of c-Fos immunoreactivity in MSN populations that express the D1 receptor or those without the D1 receptor. In these mice, the expression of the fluorescent reporter tdTomato is under the regulation of the Drd1a gene and the reporter is expressed with high selectivity and specificity only in D1(+) MSNs (Ade et al., 2011), thereby providing a direct method to assess the induction of c-Fos in both the D1 or D2-expressing sub-populations of MSNs.

Section snippets

Animals/dosing

Experiments were carried out in accordance with the Declaration of Helsinki and the Guide for the Care and Use of Laboratory Animals by the U.S. National Institutes of Health and the EU Directive 86/609/EEC. All studies were performed on male rodents. Sprague Dawley (SD) rats (Charles River Laboratories, Margate, UK), C57BL/6 mice (Taconic Biosciences, Cambridge City, IN) and BAC transgenic Drd1a-tdTomato mice (The Jackson Laboratory, Bar Harbor, ME) were acclimatized for at least 3 days

MP-10 dose-dependently increased c-Fos expression in the rat striatum

Fig. 1A shows the c-Fos immunopositive cells at two different magnifications following MP-10 at 30 mg/kg, PO, to rats. A statistically significant, dose-dependent increase in c-Fos immunopositive cells was observed in both the DLS and DMS at 10 and 30 mg/kg of MP-10 (Fig. 1B). Notably, the c-Fos signal density was higher in the DLS than the DMS at both 10 and 30 mg/kg doses. The c-Fos dominance index derived by subtracting the DMS signal from that in the DLS confirmed that MP-10 treatment at 10

Discussion

The present studies utilized a combination of pharmacological and genetic tools to test the hypothesis that PDE10A inhibition produces greater activation of D2(+) striatopallidal pathway than D1(+) striatonigral pathway. Using c-Fos as a marker of neuronal activation and a selective PDE10i tool, MP-10, we provide two major but complementary lines of evidence in support of this hypothesis. First, like the effects of the D2 inhibitory ligand, haloperidol, the effects of MP-10 were greater in the

Disclosures

J.M.W., A.M.L.O., S.L., G.G. and K.M.M. were all employees of Eli Lilly & Company during this study.

A.J.B. and T.L.B-A have no conflicts to disclose.

Acknowledgments

Expert technical assistance of Rebecca Wright is gratefully acknowledged. We thank Dr. Hong Wang for critically reading the manuscript. Funding for this study was provided by Eli Lilly & Company. The funding source had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decisions to submit the paper for publication.

References (35)

  • C.A. Strick et al.

    Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A

    Neuropharmacology

    (2010)
  • S.J. Sundquist et al.

    Fast Fos: rapid protocols for single- and double-labeling c-Fos immunohistochemistry in fresh frozen brain sections

    J. Neurosci. Methods

    (2005)
  • K.K. Ade et al.

    An improved BAC transgenic fluorescent reporter line for sensitive and specific identification of striatonigral medium spiny neurons

    Front. Syst. Neurosci.

    (2011)
  • M. Day et al.

    Differential excitability and modulation of striatal medium spiny neuron dendrites

    J. Neurosci.

    (2008)
  • K. Fujishige et al.

    Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A

    Eur. J. Biochem.

    (1999)
  • C.R. Gerfen

    The neostriatal mosaic: multiple levels of compartmental organization

    J. Neural Transm. Suppl.

    (1992)
  • S.M. Grauer et al.

    Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia

    J. Pharmacol. Exp. Ther.

    (2009)
  • Cited by (30)

    • Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease

      2021, European Journal of Pharmacology
      Citation Excerpt :

      The PDE10A inhibitors potentiate dopamine D1 receptor signaling in the striatonigral neurons, while reduce dopamine D2 receptor signaling in the striatopallidal neurons (Nishi et al., 2008). Moreover, they activate immediate early genes, as well as proenkephalin and preprotachykinin expression in striatopallidal and striatonigral neurons, respectively (Strick et al., 2010; Gentzel et al., 2015; Wilson et al., 2015). These results indicate that inhibition of PDE10A leads to concomitant activation of both striatal output systems.

    • Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening

      2018, Computational Biology and Chemistry
      Citation Excerpt :

      Typical and atypical antipsychotics with dopamine D2 receptor antagonistic activity are primary medications for the treatment of schizophrenia (Brandford, 2012). The typical antipsychotics produce extrapyramidal side effects by reducing the basal ganglia output of dopamine (Brandford, 2012; Mayo Clinic, 2018; Parr-Brownlie and Hyland, 2005; Wilson et al., 2015). Whereas the atypical antipsychotics pose a lower risk of serious side effects than do the typical medications (Mayo Clinic, 2018).

    • Investigating the role of dopamine receptor- and parvalbumin-expressing cells in extinction of conditioned fear

      2017, Neurobiology of Learning and Memory
      Citation Excerpt :

      We observed extremely low levels of cells that were co-labelled with D1R or D2R and PV in all of the regions examined, and as it follows, extremely low levels of those cells co-labelled with Fos. This was unexpected, given that dopamine has been shown to modulate the activity of PV-interneurons in both the PFC and BLA (McDonald & Mascagni, 2001; Wilson et al., 2015). D1R- and D2R-expression is predominately found on PV-interneurons compared to other interneuron subtypes in the cortex (Le Moine & Gaspar, 1998; Muly, Szigeti, & Goldman-Rakic, 1998), which suggests that most of the D1R- and D2R-expressing cells that we observed in the mPFC were pyramidal neurons rather than other types of interneurons.

    • Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D<inf>2/3</inf> receptors and sub-cortical volumes in the human basal ganglia: A PET study with <sup>18</sup>F-MNI-659 and <sup>11</sup>C-raclopride with correction for partial volume effect

      2017, NeuroImage
      Citation Excerpt :

      We did not find a statistical significant relationship of the distribution of D2/3 receptors and PDE10A enzyme in the globus pallidus. A recent study has demonstrated that the D2-enriched striato-pallidal pathways can be activated after PDE10A inhibition (Wilson et al., 2015). Therefore, although the two targets are not co-expressed in the globus pallidus, the functional activation of the D2-related pathway can probably still be mediated by PDE10A enzyme in this region.

    • Behavioral effects and neuroanatomical targets of acute atrazine exposure in the male Sprague-Dawley rat

      2017, NeuroToxicology
      Citation Excerpt :

      ATR is an inhibitor of PDEs, enzymes that cleave cyclic nucleotides, and control signaling cascades in several organs including the brain (Roberge et al., 2004, 2006). Increased c-Fos expression in the striatum of rats and mice has been shown after administration of the specific PDE10A inhibitor MP-10 (Wilson et al., 2015; Gentzel et al., 2015), thus, the regional increases in c-Fos observed in this study could be due in part to the selective inhibition of PDEs by ATR. Although currently we cannot rule out that a peripheral effect including ATR-induced gastric malaise (Hotchkiss et al., 2012) could contribute to the reduction in locomotor activity, our observations and those of others, suggest that the behavioral effect of acute ATR administration may be the result of reduced striatal release of DA plus activation of GABAergic and glutamatergic cells in the brain regions showing increased c-Fos expression.

    View all citing articles on Scopus
    View full text